609 656
[2]
Fredrick A, Erickson BA, Stensland K, Vanni AJ. Functional effects of bulbospongiosus muscle sparing on ejaculatory function and post-void dribbling after bulbar urethroplasty. J Urol 2017;197: 738–43.[3]
Wood DN, Allen SE, Andrich DE, Greenwell TJ, Mundy AR. The morbidity of buccal mucosal graft harvest for urethroplasty and the effect of nonclosure of the graft harvest side on postoperative pain. J Urol 2004;172:580–3.[4]
Versteegden LR, de Jong PK, IntHout J, et al. Tissue engineering of the urethra: a systematic review and meta-analysis of preclinical and clinical studies. Eur Urol 2017;72:594–606.
[5]
Vaegler M, Maurer S, Toomey P, Amend B, Sievert KD. Tissue engineering in urothelium regeneration. Adv Drug Deliv Rev 2014;82–83:64–8.[6]
el-Kassaby A, AbouShwareb T, Atala A. Randomized comparative study between buccal mucosal and acellular bladder matrix grafts in complex anterior urethral strictures. J Urol 2008;179:1432–6 (erratum 2490).
[7] US Food and Drug Administration. SIS plastic surgery matrix.
2004.
www.accessdata.fda.gov/cdrh_docs/pdf3/K034039.pdf.[8]
Kropp BP, Ludlow JK, Spicer D, et al. Rabbit urethral regeneration using small intestinal submucosa onlay grafts. Urology 1998;52: 138–42.
[9]
Aufderklamm S, Vaegler M, Kelp A, et al. Collagen cell carriers seeded with human urothelial cells for urethral reconstructive surgery: first results in a xenograft minipig model. World J Urol 2017;35:1125–32.
[10]
Bhargava S, Patterson JM, Inman RD, MacNeil S, Chapple CR. Tissue- engineered buccal mucosa urethroplasty-clinical outcomes. Eur Urol 2008;53:1263–9.[11]
Ribeiro-Filho LA, Sievert KD. Acellular matrix in urethral recon- struction. Adv Drug Deliv Rev 2015;82–83:38–46.[12]
Damaser MS, Sievert KD. Tissue engineering and regenerative medicine: bench to bedside in urology. Adv Drug Deliv Rev 2015;82–83, v[5_TD$DIFF]
–vii.[13]
Ram-Liebig G, Bednarz J, Stuerzebecher B, et al. Regulatory chal- lenges for autologous tissue engineered products on their way from bench to bedside in Europe. Adv Drug Deliv Rev 2015;82– 83:181–91.
[14]
Knoepfler PS. From bench to FDA to bedside: US regulatory trends for new stem cell therapies. Adv Drug Deliv Rev 2015;82– 83:192–6.
[15] US Food and Drug Administration. FDA regulation of human cells,
tissues, and cellular and tissue-based products (HCT/P’s) product
list. 2009.
www.fda.gov/biologicsbloodvaccines/tissuetissuepro- ducts/regulationoftissues/ucm150485.htm.[16]
Sievert KD, Amend B, Stenzl A. Tissue engineering for the lower urinary tract: a review of a state of the art approach. Eur Urol 2007;52:1580–9.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 6 0 7 – 6 0 9
609